Bickerstaff's encephalitis

Bickerstaff's Encephalitis

Bickerstaff's encephalitis is a rare neurological disorder characterized by acute inflammation of the brainstem and peripheral nervous system. It is named after the British neurologist Edwin Bickerstaff, who first described the condition in 1951. The disorder is often associated with Guillain-Barré syndrome and Miller Fisher syndrome, sharing some clinical features and pathophysiological mechanisms.

Clinical Features

Bickerstaff's encephalitis typically presents with a rapid onset of symptoms, which may include:

• Ophthalmoplegia: Paralysis or weakness of the eye muscles, leading to double vision or difficulty moving the eyes.
• Ataxia: Lack of voluntary coordination of muscle movements, often resulting in gait disturbances.
• Altered consciousness: Ranging from drowsiness to coma.
• Hyperreflexia: Exaggerated reflexes.
• Babinski sign: An abnormal reflex indicating central nervous system involvement.

Pathophysiology

The exact cause of Bickerstaff's encephalitis is not fully understood, but it is believed to be an autoimmune disorder. The immune system mistakenly attacks the body's own tissues, particularly targeting the brainstem and peripheral nerves. This autoimmune response is often triggered by a preceding infection, such as a respiratory or gastrointestinal infection.

Diagnosis

Diagnosis of Bickerstaff's encephalitis is primarily clinical, supported by laboratory and imaging studies. Key diagnostic tools include:

• Lumbar puncture: Analysis of cerebrospinal fluid (CSF) may show elevated protein levels and pleocytosis.
• Magnetic Resonance Imaging (MRI): May reveal abnormalities in the brainstem.
• Electromyography (EMG) and nerve conduction studies: To assess peripheral nerve involvement.
• Serological tests: Detection of anti-GQ1b antibodies, which are often present in patients with Bickerstaff's encephalitis.

Treatment

Treatment of Bickerstaff's encephalitis focuses on managing symptoms and modulating the immune response. Common therapeutic approaches include:

• Intravenous immunoglobulin (IVIG): To neutralize harmful antibodies and modulate the immune system.
• Plasmapheresis: A procedure to remove antibodies from the blood.
• Corticosteroids: To reduce inflammation.

Prognosis

The prognosis for Bickerstaff's encephalitis varies. Many patients experience significant recovery, although some may have residual neurological deficits. Early diagnosis and treatment are crucial for improving outcomes.

Also see

• Guillain-Barré syndrome
• Miller Fisher syndrome
• Autoimmune encephalitis
• Ophthalmoplegia

edit 

WikiMD neurology

External links

• Comprehensive information from the National Institute of health.
  

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z